TLR2遺伝子多型とヘリコバクター・ピロリ:論争のある関連の再訪
Duygu Kirkik1,2, Sevgi Demircioglu3, Sevgi Kalkanli Taş1
1Department of Immunology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkiye.
Upsala journal of medical sciences
|January 8, 2026
まとめ
このメタアナリシスでは、Toll様受容体2(TLR2)遺伝子多型(rs3804099、del -196から-174)とヘリコバクター・ピロリ感染リスクとの関連は見出されなかった。宿主の遺伝子型だけでは、H.ピロリ感染に対する感受性の違いを説明することはできない。
科学分野:
- 免疫遺伝学; 微生物学; 集団遺伝学
背景:
- Toll様受容体2(TLR2)の多型は、ヘリコバクター・ピロリ感染感受性における宿主遺伝的要因として調査されています。
研究 の 目的:
- メタアナリシスを通じて、2つの一般的なTLR2多型、rs3804099およびdel -196から-174が、多様な集団におけるH.ピロリ感染リスクに及ぼす寄与を明らかにすること。
主な方法:
- PubMed、Scopus、Web of Scienceで2025年1月までの症例対照研究の系統的文献検索を実施しました。
主要な成果:
- 10件の研究(4,521人の被験者)を分析しました。
- TLR2 rs3804099またはdel -196から-174多型とH.ピロリ感染リスクとの間に、様々な遺伝子モデル(対立遺伝子、優性、劣性、ホモ接合体、ヘテロ接合体)において有意な関連は見られませんでした。
- 特にrs3804099については、研究間の実質的な異質性が認められましたが、感度分析により、プールされた結果の頑健性が確認されました。
結論:
- このメタアナリシスは、TLR2 rs3804099またはdel -196から-174多型とH.ピロリ感染との間の、一貫した遺伝的関連を否定するものです。
関連する概念動画
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
532
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
532
Peptic Ulcer Disease I: Introduction
734
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
734
Gastritis-II: Pathophysiology
1.2K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.2K
Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K


